Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Resection Rate of Liver Metastases Following Neoadjuvant Therapy With Avastin in Combination With Oxaliplatin and Capecitabine (XELOX) in Patients With Metastatic Colorectal Cancer With Unresectable Liver Metastasis

NCT00700570 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00700570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Resection Rate of Liver Metastases Following Neoadjuvant Therapy With Avastin in Combination With Oxaliplatin and Capecitabine (XELOX) in Patients With Metastatic Colorectal Cancer With Unresectable Liver Metastasis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
November 30, 2011
Enrollment
45 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer